Huge variations between countries in time for reimbursement decisions on new cancer drugs

Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average decision time is longer than one year in some countries, according to a study to be reported at ESMO 2018 Congress.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

HTA [+]    European Medicines Agency [+]    EMA [+]    ESMO 2018 [+]   

More #news: